Daiichi Sankyo to acquire 2% of own shares
This article was originally published in Scrip
The board of Daiichi Sankyohas approved a new buyback plan under which the firm will acquire up to 15 million of its own outstanding ordinary shares for a maximum of ¥50 billion ($470.0 million) over the July-August period. The total represents around 2% of the company's outstanding shares. Takeda is planning to cancel around 2% of its shares under a similar programme, as part of efforts by major Japanese pharma firms to improve shareholder returns and to guard against any potential hostile takeover bid through the open market.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.